الفهرس 
Epidemiology and Pathogenesis of HemangiomaOnly 14 pages are availabe for public view
 |  | from | 131 |  |  |
| | | from | 131 | | |
Abstract
Propranolol effectiveness on infantile hemangiomas (IHs) has been fortuitously observed. The mechanisms of action of propranolol on IHs are still poorly understood, but, since 2008, many reports have confirmed its efficacy.
Propranolol is indicated in case of life threatening IHs, in case of functional consequences of the IH, or a risk of permanent disfigurement. After excluding contraindications, oral propranolol should be administered at the dose of 2–3 mg/kg/day for 6 months, about 10–15 % of infants needed to be retreated for 3–6 months more, especially if they present a large segmental IH and/or an IH with a deep component. Local beta-blockers, such as timolol, could be used for superficial IHs.
Most of the time multimodal management of complicated IHs includes medical treatment in order to control the growth of the tumor. No official treatment guidelines for the treatment of IH are available; however, given the recent proven rapid efficacy and safety of betablockers in the therapy of IHs, many teams advise oral propranolol as a first- line therapy.